**CONFIDENTIAL      TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF **

**THIS      DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY **

**FILED      WITH THE COMMISSION.*****

**MARKETING      AND PROMOTION AGREEMENT**

**THIS      MARKETING AND PROMOTION AGREEMENT**
**Agreement**
**Effective      Date**
**King**
**Inyx**

**WHEREAS**

**WHEREAS,**

**WHEREAS**
**Collaboration      Agreement**

**NOW**
**      THEREFORE**

| **1.** | **DEFINITIONS** |
|--------|-----------------|

|   | (a) | **Definitions.**(b)                Unless otherwise specifically defined in this Agreement, each capitalized                term used herein will have the meaning assigned to such term in the                Collaboration Agreement. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | In                addition to the terms defined elsewhere herein, as used in this Agreement,                the following terms have the meanings specified below when used in                this                Agreement: |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Agreement**

**Baseline      Amounts**

**Collaboration      Agreement**

**Commercially      Reasonable Efforts**

**CONFIDENTIAL          TREATMENT**

----

**Copromotion      Date**

**Detail(s)**
**Detailing**

**Detail      Cost**

**Details      Shortfall**

**Effective      Date**

**Electing      Party**

**Excess      Details**

**Exaeris**

**Initiation      Date**

**Inyx**

**Inyx      Detail Report**

**King**

**King      Detail Report**

**King      Summary Sales Report**

**CONFIDENTIAL          TREATMENT**

----

**Marketing      Data**

**Marketing      Materials**

**Minimum      Targeted Details**

**Nonelecting      Party**

**Nonperforming      Party**

**Offset      Amount**

**PDMA**

**Performing      Party**

**Physicians**
*i.e.*

**Primary      Detail(s)**

**Subject      Quarter**

**Term**

**Trademark**

|   | **1.2** | **Interpretation**.                When a reference is made in this Agreement to Articles, Sections,                Exhibits, or Schedules, such reference will be to an Article or Section                of                or Exhibit or Schedule to this Agreement unless otherwise indicated.                The                headings contained in this Agreement are for reference purposes only                and                will not affect in any way the meaning or interpretation of this                Agreement. Whenever the words “include,”“includes,” or “including” are                used in this Agreement, they will be deemed to be followed by the                words                “without limitation.” Unless the context otherwise requires, (i) “or” is                disjunctive but not necessarily exclusive, (ii) words in the singular                include the plural and vice versa, and (iii) the use in this Agreement                of                a pronoun in reference to a party hereto includes the masculine,                feminine,                or neuter, as the context may require. The Schedules and Exhibits                hereto                will be deemed part of this Agreement and included in any reference                to                this Agreement. This Agreement will not be interpreted or construed                to                require any Person to take any action, or fail to take any action,                if to                do so would violate any applicable                law. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| **2.** | **GRANT                OF RIGHTS TO INYX** |
|--------|--------------------------------------------|

|   | **2.1** | **Copromotion                Rights**.                King hereby grants to Inyx and its Affiliates, on a non-exclusive                basis,                together with King and its Affiliates, the right to promote the Products                in the Territory during the Term of this Agreement, upon and subject                to                the terms and conditions set forth in this Agreement; provided that                the                license to promote a particular Product will only be effective on                the                Initiation Date of such Product in the applicable country of the                Territory                in which such Product has received Regulatory Approval and only for                so                long as such Product has Regulatory Approval in such country. The                parties                acknowledge and agree that, during the Term, the license granted                to Inyx                under Section 4.1 of the Collaboration Agreement will include a                non-exclusive right under the Technology and Patent Rights to sell,                offer                for sale, and import the Products in the Territory, subject to the                terms                of this Agreement and the Collaboration                Agreement. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **2.2** | **Trademark**. |
|--------|---------|----------------|

|   | (a) | Required                Use and Compliance.                Inyx will promote the Products only under the Trademarks, which as                of the                Effective Date are listed on Schedule 2.2 attached hereto, which                schedule                will be updated from time to time during the                Term. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Validity                of Trademarks.                Inyx acknowledges that King will have sole and exclusive ownership                of all                right, title, and interest on a worldwide basis, with full rights                to                license or sublicense, subject to the licenses granted Inyx hereunder,                in                and to any and all Trademarks. Inyx understands and agrees that it                will                not have, assert, or acquire any right, title, or interest in or                to any of                the Trademarks. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Use                of Trademarks.                In connection with the subject matter hereof, Inyx will maintain                quality                standards for all of its uses of the Trademarks in connection with                the                Products that are substantially equivalent to or, at King’s option,                stricter than those standards used by King in connection with its                promotion of the Products. Subject to the foregoing, Inyx acknowledges                and                agrees that King has the right, at any time, to modify or supplement                such                quality standards and that Inyx must implement such new standards                or                changes following receipt of notice of such additions or changes.                In order                to determine whether Inyx is in compliance with this Section 2.2(c),                at                the reasonable written request of King, and at Inyx’s expense, Inyx: (i)                will provide King with copies, photographs, or representative samples                of                its advertising copy, promotional materials, or other materials bearing                any of the Trademarks; and (ii) upon reasonable notice and during                normal                business hours, will provide to King or its representatives access                to                Inyx’s premises. Inyx covenants and agrees that it will not use any                Trademarks in connection with any goods or products other than the                Products, notwithstanding that such goods or products are dissimilar                to                the Products or have a different use. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **2.3** | **Sublicensee.**                The parties acknowledge that Inyx may sublicense its rights granted                hereunder to Exaeris Inc. (“**Exaeris**”);                provided that Exaeris agrees, in writing, to be bound by the terms                of this                Agreement and the applicable terms of the other Collaboration Documents,                including the confidentiality and assignment provisions thereof;                and                provided further that the right to sublicense to Exaeris will immediately                terminate at such point as Exaeris is no longer a wholly owned subsidiary                of Inyx. As of the Effective Date, Inyx represents and warrants that                Exaeris is a wholly owned subsidiary of Inyx. Inyx acknowledges and                agrees                that, as provided in Section 4.2 of the Collaboration Agreement,                Inyx will                remain liable for all obligations, including obligations to perform,                under                this Agreement and for all actions of Exaeris under such sublicense.                Notwithstanding such sublicense, Exaeris will not be deemed a third                party                beneficiary under this Agreement. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **3.** | **RESPONSIBILITIES                OF INYX** |
|--------|---------------------------------------------|

|   | **3.1** | **Promotion                by Inyx**.                (a)                With respect to each Product, commencing as of the Initiation Date                relating to such Product and continuing throughout the Term, Inyx                will use                its Commercially Reasonable Efforts to promote such Product in the                Territory in accordance with the then current Marketing Plan and                Budget.                The nature of the promotion of the Products required as part of Inyx’s                promotion obligations hereunder will be determined by the AMC and                set                forth in then-current Marketing Plan and Budget, but such obligations                may                include the following: |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | Detailing                the Products to Physicians in the                Territory; |
|--------|-----|--------------------------------------------------------------------------------------|

|   | (ii) | meeting                targeted and minimum quarterly Detail requirements;                and |
|--------|------|-----------------------------------------------------------------------------------------------|

|   | (iii) | attendance                at specified medical conventions to promote the                Products. |
|--------|-------|----------------------------------------------------------------------------------------------------|

|   | (b) | Until                the AMC determines otherwise, all Details that Inyx is required to                perform                pursuant to this Article 3 shall be Primary Details with respect                to                Intal. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | In                performing its duties hereunder, Inyx will, and will cause its employees                and the employees of its relevant Affiliates to, comply with all                regulatory, professional, and legal requirements, including the FDA’s                regulations and guidelines concerning the advertising of prescription                drug                products, the American Medical Associations’ Guidelines on Gifts to                Physicians, the PhRMA Guidelines for Marketing Practices, and the                ACCME                Standards for Commercial Support of Continuing Medical Education,                which                may be applicable to the services (including the warehousing, handling,                and distribution of the Products and Products samples) to be provided                by                Inyx hereunder. No employee of Inyx or of any of its relevant Affiliates                will make any representation, statement, warranty, or guaranty with                respect to the Products that is not consistent with current labeling                of                the Products or promotional materials approved by the AMC, that is                deceptive or misleading, or that disparages the Products or the good                name,                good will, or reputation of King. Inyx represents and warrants that                its                services hereunder will be provided in a professional, ethical, and                competent manner. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **3.2** | **Inyx                Sales Force**.                Inyx agrees that, immediately after the Effective Date, Inyx or its                Affiliates will begin developing a specialty sales force for purposes                of                fulfilling its obligations hereunder consisting of at least *** field                sales representatives and ancillary sales support staff. Without                limiting                the obligations to use Commercially Reasonable Efforts, Inyx must                demonstrate to the reasonable satisfaction of the AMC, as evidenced                by                written approval from the AMC, that such sales force has been developed                and fully organized and has completed a core training program on                the                Products conducted by King, as well as sales effectiveness training                conducted by King under guidelines agreed by the AMC. After Inyx                has                demonstrated the foregoing, Inyx may begin Detailing the Products.                Beginning on the date of the first such Detail (such date, the                “**Copromotion                Date**”),                and continuing thereafter throughout the Term, Inyx agrees that it                will                have at least *** field sales representatives and ancillary sales                support                Detailing the Products and conducting other active promotion in the                Territory, except as otherwise agreed to by the parties. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **3.3** | **Costs                of Inyx Sales Force**. (a)                Until the Copromotion Date, except as agreed to by the parties, and                subject to the terms and conditions of this Agreement, Inyx will                be solely                responsible for the costs and expenses of establishing and maintaining                Inyx’s (and its Affiliates’) sales force of the size required by Section                3.2, and conducting Inyx’s other activities under this Agreement;                following the Copromotion Date, such costs and expenses of Inyx will                be                deemed Collaboration Costs. Notwithstanding the foregoing, Inyx will                pay                incentive compensation to its sales representatives having primary                responsibility for Detailing the Products with respect to sales of                the                Products in the Territory in accordance with Inyx’s incentive compensation                plans for its own products, it being understood that Inyx will determine                the target payout for the Products in a manner consistent with the                way in                which it determines the target payouts for prescription drug products                of                comparable commercial potential. In connection with the development                of                Inyx’s sales force, (i) all training will be conducted in accordance                with Section 5.1, (ii) the content and strategic direction                of any                training provided by Inyx that relates specifically to the Products                will                be coordinated with the AMC, and (iii) all costs with respect to                training                Inyx’s sales force with respect to the Products will be deemed                Collaboration Costs. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | (b) | To                the extent practicable, all written, electronic, and visual communications                provided to any of Inyx’s (and its Affiliates’) sales representatives                regarding strategy, positioning, or selling messages for the Products                will, at the request of the AMC, be subject to review by the AMC                in                accordance with                Section 5.2(a). |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **3.4** | **Inyx                Detail Reports**.                Commencing on the Initiation Date and throughout the Term, Inyx will                provide the AMC and King with a report (each an “**Inyx                Detail Report**”)                within thirty (30) calendar days after the end of each Calendar Quarter,                with the first such report due for the Calendar Quarter during which                the                Initiation Date occurs, setting forth the following information regarding                the efforts of Inyx’s sales representatives in promoting and Detailing the                Products during the preceding quarter (or part thereof): (i) the                number of Details made and recorded by Inyx’s standard record keeping                procedures, and approved by the AMC, based on data recorded by the                sales                representatives; (ii) the names and addresses of the Physicians                called upon and the date of the Detail; (iii) the percentage                of                Physicians Detailed who were provided with samples of the Products;                (iv) the actual number of such samples delivered on each Detail                and                the dates of such delivery; (v) a breakdown of all information required                to                be contained in each report on an individual sales representative                and                aggregate basis; and (vi) such other information as may be                required                in the then current Marketing Plan and Budget. Each such Inyx Detail                Report will be in an electronic format and in hard copy form. Inyx                will                also provide King on-request access to all call reporting data at                the                lowest level of information content, through file extraction or electronic                query, Detailing and sampling data at the Physician-sales representative                level, including such measures as prescriptions, decile, target status,                products Detailed, order of the Detail, products, and quantity sampled.                This data shall be in the electronic format readily used by analytic                functions such as market research or business                analysis. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **4.** | **RESPONSIBILITIES                OF KING** |
|--------|---------------------------------------------|

|   | **4.1** | **Marketing                by King**. (a)                With respect to each Product, commencing as of the Initiation Date                relating to such Product and continuing throughout the Term, King                will use                its Commercially Reasonable Efforts to market and promote the Products                in                the Territory in accordance with the then current Marketing Plan                and                Budget. The nature of the promotion of the Products required as part                of                King’s marketing obligations hereunder will be determined by the AMC and                set forth in then-current Marketing Plan and Budget, but such obligations                may include the following: |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | marketing                and promoting the Products to Physicians in the                Territory; |
|--------|-----|----------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | (ii) | meeting                targeted and minimum quarterly Detail requirements;                and |
|--------|------|-----------------------------------------------------------------------------------------------|

|   | (iii) | attendance                at specified medical conventions to promote the                Products. |
|--------|-------|----------------------------------------------------------------------------------------------------|

|   | (b) | In                addition, King will provide the following marketing support for the                Products: (i) direct marketing to Physicians that are high-potential                primary care prescribers; and (ii) development and maintenance of                a                marketing database, which includes contract information, response                data,                behavioral data, demographic data, and attitudinal data (collectively,                “**Marketing                Data**”).                King will provide Inyx with access to the Marketing Data, including                all                primary and secondary market data and research, and historical data                as may                be reasonably requested by Inyx; provided, however, that the sharing                of                any purchased data by King with Inyx will be subject to the approval                of                the data sources; and provided further that all such Marketing Data                will                be deemed the Confidential Information of                King. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | In                performing its duties hereunder, King will, and will cause its employees                and the employees of its relevant Affiliates to, comply with all                regulatory, professional, and legal requirements, including the FDA’s                regulations and guidelines concerning the advertising of prescription                drug                products, the American Medical Associations’ Guidelines on Gifts to                Physicians, the PhRMA Guidelines for Marketing Practices, and the                ACCME                Standards for Commercial Support of Continuing Medical Education,                which                may be applicable to the services (including the warehousing, handling,                and distribution of the Products and Products samples) to be provided                by                King hereunder. No employee of King or of any of its relevant Affiliates                will make any representation, statement, warranty, or guaranty with                respect to the Products that is not consistent with current labeling                of                the Products or promotional materials approved by the AMC, that is                deceptive or misleading, or that disparages the Products. King represents                and warrants that its services hereunder will be provided in a                professional, ethical, and competent                manner. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **4.2** | **Costs                of King Sales Force**. (a)                From the Effective Date, except as agreed to by the parties and subject                to                the terms and conditions of this Agreement, to the extent King elects                to                have a sales force, King will be solely responsible for the costs                and                expenses of establishing, maintaining, and training such sales force                of                King (and its Affiliates); provided that all such costs and expenses                incurred will be deemed Collaboration Costs. In connection with the                foregoing, (i) such training will be conducted in accordance with                Section                5.1 and (ii) the content and strategic direction of any training                provided                by King that relates specifically to the Products will be coordinated                with                the AMC. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | (b) | To                the extent practicable, all written, electronic, and visual communications                provided to any of King’s (and its Affiliates’) sales representatives                regarding strategy, positioning, or selling messages for the Products                will, at the request of the AMC, be subject to review by the AMC                in                accordance with Section 5.2(a). |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **4.3** | **King                Detail and Sales Reports**. (a)                Commencing on the Initiation Date and throughout the Term, if King                elects                to establish, and at such time as King has established, a sales force,                King will provide the AMC and Inyx with a report (each a “**King                Detail Report**”)                within thirty (30) calendar days after the end of each Calendar Quarter,                with the first such report due for the Calendar Quarter during which                such                sales force has been established, setting forth the following information                regarding the efforts of King’s sales force in promoting and Detailing the                Products during the preceding quarter (or part thereof): (i) the                number of Details made and recorded by King’s standard record keeping                procedures, and approved by the AMC, based on data recorded by the                sales                representatives; (ii) the names and addresses of the Physicians                called upon; (iii) the percentage of Physicians Detailed who                were                provided with samples of the Products; (iv) the average number                of                such samples delivered on each Detail; (v) a breakdown of all information                required to be contained in each report on an individual sales                representative and aggregate basis; and (vi) such other information                as may                be required in the then current Marketing Plan and Budget. Each such                King                Detail Report will be in an electronic format and in hard copy                form. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Commencing                on the Initiation Date and throughout the Term, within fifteen (15)                days                after the end of each month, King will provide to the AMC and Inyx                a                summary report (each a “**King                Summary Sales Report**”)                setting forth the gross sales of the Products in the Territory for                such                month, the gross sales of the Products in the Territory since                January 1 of such year, and the itemized deductions taken                in                calculating all Net Sales with respect to such gross sales, the Net                Sales                of the Products in the Territory for such month, and the Net Sales                of the                Products in the Territory since January 1 of such year. All                reports                required by this Section 4.3(b) will be provided to the AMC and Inyx                either by facsimile or transmitted electronically, in each ease with                a                confirmation copy sent by mail. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Commencing                on the Initiation Date and throughout the Term, King will furnish                to the                AMC and Inyx, within thirty (30) calendar days after the end of each                Calendar Quarter (including the final Calendar Quarter), a report                setting                forth in reasonable detail the calculation of the total Net Sales                of                Products in the Territory for such Calendar Quarter in a form approved                by                the AMC. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **4.4** | **Shipment,                Billing of the Product**.                King (and its Affiliates) will have the sole responsibility for the                shipment, distribution, warehousing, billing, and order confirmation                of                all Products and for the collection of receivables resulting from                sales of                the Products in the Territory. AMC may make recommendations to King                from                time to time regarding the price of and pricing strategies for the                Products during the Term, including, without limitation, price increases                and decreases and the timing thereof; provided, however, that King                will                have the sole authority to determine the price of the Products during                the                Term, including price increases and decreases and the timing thereof.                During the term of the Manufacturing and Supply Agreement, the manufacture                of the Products and Product samples will be in accordance with the                terms                of such agreement, and Inyx will ensure that adequate quantities                of the                Products and Product samples are available to meet the anticipated                demand                for the Products and Product samples during the Term of this Agreement.                Thereafter, King will manufacture or cause to be manufactured the                Products                and Product samples in accordance with all applicable laws and will                use                its Commercially Reasonable Efforts to ensure that adequate quantities                of                the Products and Product samples are available to meet the anticipated                demand for the Products and Product samples during the Term of this                Agreement. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **4.5** | **Product                Pricing**.                King (and its Affiliates) will have sole responsibility for setting                the                Product price or offering discounts to customers. The AMC will make                recommendations to King, or its internal pricing committee, on either                the                wholesale average costs price or any discount deemed necessary to                maintain                an effective market position. King, or its pricing committee, will                take                such recommendations under advisement, but King will retain ultimate                authority with regard to price and                discounts. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **5.** | **TRAINING                AND PROMOTIONAL MATERIAL** |
|--------|------------------------------------------------------|

|   | **5.1** | **Training**. (a)                Each of the parties agrees to make its sales representatives available                for                training with respect to the marketing and sale of the Products.                The                parties agree that King will, subject to the AMC’s approval, be                responsible for developing and conducting training programs for each                of                Inyx’s and King’s sales forces, with all costs associated with so                developing and conducting to be deemed Collaboration Costs. Inyx                will                participate in conducting such training to the extent requested by                King.                Training will be carried out at a time that is mutually acceptable                to the                parties and will be conducted on an ongoing basis to assure a consistent,                focused promotional strategy. As additional members are added to                the                parties’ respective sales forces responsible for marketing or promoting                the Products, training will be given to groups of the newly selected                members. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | The                AMC will decide where the training of each party’s sales representatives                will occur, and the costs of transporting, housing, and maintaining                the                parties’ respective personnel for such training, to the extent included in                the Marketing Plan and Budget, will be deemed Collaboration Costs.                Subject                to the oversight of the AMC, all sales and marketing training materials                will be prepared and supplied by King, and the cost of such training                materials will be included as part of the Collaboration                Costs. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **5.2** | **Promotional                Materials**. (a)                All written sales, sales training, Detailing aids, promotional, and                advertising materials (“**Marketing                Materials**”)                relating to the Products will be prepared by King, with such materials                being consistent with standards and guidelines approved by the AMC.                All                Marketing Materials developed by King will be reviewed and approved                in                accordance with King’s established copy clearance process. Upon final                approval of all Marketing Materials, King will be responsible for                printing                such approved Marketing Materials and providing Inyx with sufficient                copies thereof. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | In                all written or visual materials related to the Products that identify                either of the parties, the parties will be presented and described                to the                medical communities (including, for example, the physician, pharmacy,                governmental, reimbursement, and hospital sectors) as joining in                the                promotion of the Products in the Territory. All such written and                visual                materials and all documentary information, promotional material,                and oral                presentations (where practical) regarding the promoting of the Products                will state this arrangement and will display the names and logos                of the                parties with equal prominence, as permitted by applicable                law. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | All                costs and expenses associated with the preparation and distribution                of                such Marketing Materials will be included in the Marketing Plan and                Budget                and will be deemed Collaboration                Costs. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | All                Marketing Materials will be deemed Improvements and will be subject                to the                provisions of Article 5 of the Collaboration Documents. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **6.** | **PRODUCT                SAMPLES** |
|--------|------------------------------------|

|   | **6.1** | **Supply,                Storage, and Distribution of Samples**. (a)                Inyx will provide King, from time to time on a schedule and in such                quantities to be reasonably determined by the AMC, with samples of                the                Products to be used by the parties for marketing and promoting the                Products in the Territory. Inyx will ship the samples to one central                warehouse of King, as designated by King, and the risk of loss and                responsibility for handling and warehousing of the samples will pass                to                King upon delivery to such                warehouse. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Inyx                and King will be responsible for distributing the samples of the                Products                to their respective sales forces in a timely manner. Each party will                also                be responsible for securing the return of and reconciling existing                sample                inventories from discontinued field sales representatives. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | (c) | All                Products samples provided to King and Inyx sales representatives                hereunder                will be accompanied by an appropriate Certificate of Analysis of                the                Products specifications and an indication of expiration                dating. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **6.2** | **Use                of Samples**. (a)                Each party will be responsible for accountability and compliance                with the                PDMA, and other applicable federal, state, and local laws and regulations                relating to such samples or the distribution of same. Inyx and King                each                will be responsible for adherence by its respective sales representatives                to such laws and regulations. Each party or its appointed agents                will have                the right to audit the records and/or reports for the Products samples,                as                required to be kept by the other party under the PDMA, pursuant to                the                provisions of Article 10 of the Collaboration                Agreement. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **6.3** | **Cost                of Samples**. (a)                All costs and expenses associated with the manufacture, shipment,                warehousing, storage, and distribution of Products samples will be                included in the Marketing Plan and Budget and will be deemed Collaboration                Costs. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **7.** | **CERTAIN                REGULATORY MATTERS** |
|--------|-----------------------------------------------|

|   | **7.1** | **Licenses**.                Each party hereto will, at its sole cost and expense, maintain in                full                force and effect all necessary licenses, permits, and other authorizations                required by law, regulation, ordinance, or statute to carry out its                duties                and obligations under this                Agreement. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **7.2** | **Regulatory                Responsibility**.                As provided in Article 9 of the Collaboration Agreement, King will                be                responsible for all regulatory matters regarding the Products, subject                to                AMC oversight; provided, however, that King will provide Inyx with                copies                of all communications received from any Regulatory Authority concerning                the Products or any Marketing                Materials. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **7.3** | **Efficacy                and Safety Information**.                King will furnish Inyx with efficacy and safety information reasonably                requested by Inyx to assist Inyx in promoting the Products to Physicians                in the Territory, including relevant clinical and safety data included                in                the NDA for the Products and additional information, if any, related                to                the efficacy and safety profile of the Products since the Products’                approval by the applicable Regulatory Authority. King will also provide                Inyx with updates to annual reports required to be delivered by King                pursuant to this Agreement. Except for that information that is to                be                disclosed to Physicians in connection with conducting Details, such                information will be treated as the Confidential Information of                King. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **7.4** | **Returns**.                Any Products returned to Inyx will be shipped directly to King’s or its                designee’s nearest facility, with shipping and other direct costs to be                deemed Collaboration Costs. Inyx will incur no liability or any nature                in                the handling of such returns unless such Products were stored improperly                by Inyx. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| **8.** | **NET                SALES SHARING AND EXPENSES** |
|--------|---------------------------------------------------|

|   | **8.1** | **Net                Sales Sharing**. (a)                From the Effective Date until the Copromotion Date, King will retain                all                Net Sales of Products. Following the Copromotion Date, the parties                agree                to share the Net Sales in the following manner: |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | with                respect to annual Net Sales of Products up to and including the amount                for                such Calendar Year set forth in Schedule 8.1 attached hereto (the                “**Baseline                Amounts**”),                King will retain *** of the Net Sales, and Inyx will be entitled                to the                remaining ***; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | with                respect to annual Net Sales of Products above the Baseline Amounts                for                such Calendar Year, King will retain *** of the Net Sales, and Inyx                will                be entitled to the remaining ***. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | As                provided in Section 4.3(c), following the Initiation Date, King will                provide to the AMC an accounting of all Net Sales received by it                with                respect to all Products. Within fifteen (15) days thereafter, the                AMC will                produce a report setting forth the calculation of Net Sales and its                allocation between the parties in accordance with this Section 8.1.                The                report will also set forth the amount of any payments that King must                make                to Inyx in order to achieve such apportionment between the parties.                All                such payments, subject to Section 8.2(c), will be made within sixty                (60)                days following the end of the applicable Calendar Quarter. As provided                in                Section 4.4, King will book all Net Sales, and distribute same to                Inyx in                accordance with this Section 8.1, and King will be responsible for                all                billing and collection activities with respect to Net Sales. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | All                Net Sales incurred in currencies other than U.S. Dollars will be                converted                to U.S. Dollars based on the exchange rate quoted in The Wall Street                Journal, NY Edition on the last business day of the applicable Calendar                Quarter. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **8.2** | **Marketing                Costs**. (a)                In                accordance with Article 3 of the Collaboration Agreement, King and                Inyx                will develop, and the AMC will approve, a Marketing Plan and Budget,                which                will include the Collaboration Costs to be incurred by the parties,                including Marketing Costs. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Each                party understands and acknowledges that all Collaboration Costs incurred                by a party on and after the Effective Date will *** and that each                party                will submit the reports with respect to Collaboration Costs required                under                Article 3 of the Collaboration                Agreement. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | To                the extent the amounts owed to King for Collaboration Costs, including                Marketing Costs, with respect to a particular Calendar Quarter exceed                the                amounts owed to Inyx for Collaboration Costs with respect to such                Calendar                Quarter (such difference, the “**Offset                Amount**”),                King may deduct as credits from payment of Inyx’s portion of Net Sales due                under Section 8.1 such Offset Amount. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **8.3** | **Excess                Detail Costs**.                With respect to any Calendar Quarter during the Term at such time                as King                has developed a sales force, if a party (the “**Electing                Party**”)                determines, based on the Inyx Detail Reports or the King Detail Reports,                as the case may be, that the other party is failing to conduct the                minimum                number or percentage of Details (such minimum, the “**Minimum                Targeted Details**,”                and the difference between such minimum and the number of Details                actually                conducted, the “**Details                Shortfall**”)                required to be conducted by such other party in such Calendar Quarter                (the                “**Subject                Quarter**”)                by the Marketing Plan and Budget for such quarter, then the Electing                Party, so long as it has conducted its Minimum Targeted Details for                the                Subject Quarter, may elect to conduct a greater number of Details                than the                Minimum Targeted Details for such Electing Party (such greater number                of                Details, the “**Excess                Details**”)                pursuant to the terms of this Section 8.3. In such event, the Electing                Party will notify the other party (the “**Nonelecting                Party**”)                within ten (10) days of the Electing Party’s receipt of the Inyx Detail                Reports or King Detail Reports, as applicable, reflecting the Details                Shortfall. Following such notice, the Nonelecting Party will have                until                the end of the Calendar Quarter immediately following the Subject                Quarter                to cure its failure by providing a sufficient number of Details to                meet                the Nonelecting Party’s Minimum Targeted Details for such immediately                following Calendar Quarter and make up for such Details Shortfall                from the                Subject Quarter. If the Nonelecting Party fails to so cure such Details                Shortfall within such time period, the Electing Party may conduct                a number                of Excess Details in the next succeeding Calendar Quarter equal to                the                Details Shortfall of the Nonelecting Party; and, within thirty (30)                days                after delivery of notice by the Electing Party of the Excess Details                so                conducted, the Nonelecting Party will pay to the Electing Party an                amount                equal to the then-current Detail Cost multiplied by the number of                Excess                Details. Notwithstanding the foregoing, the prior approval of the                AMC will                be required for any payments to an Electing Party under this Section                8.3                on Excess Details in excess of *** of the Minimum Targeted Details                for                such Electing Party for the Subject Quarter. In addition, at the                end of                each Calendar Year, the AMC, after review of the Details conducted                by, and                the Minimum Targeted Details allocated to, each party during such                Calendar                Year, may require the Nonelecting Party to pay the Electing Party                for any                Excess Details conducted by the Electing Party during such Calendar                Year                and not previously reimbursed by the Nonelecting                Party. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **9.** | **TERM                AND TERMINATION** |
|--------|-----------------------------------------|

|   | **9.1** | **Term                of Agreement**.                The term of this Agreement (the “**Term**”)                will commence as of the Effective Date hereof and will continue until                the                later of December 31, 2015 and the last date on which any Approved                New                Product is sold, unless terminated sooner or extended as provided                below. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **9.2** | **Termination                by Either Party**. (a)                Each                party will have the right to terminate this Agreement at any time                upon                written notice to the other party, if such other party breaches in                a                material way any of the representations, warranties, covenants, or                agreements set forth in this Agreement or otherwise materially defaults                in                the performance of any of its duties or obligations under this Agreement,                which breach or default is not cured within sixty (60) days after                written                notice is given to the breaching party specifying the breach or default. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Each                party may, by written notice delivered to the breaching party, terminate                this Agreement if there are two or more similar or substantially                similar                material breaches of this Agreement by the breaching party within                any                12-month period, which termination will be effective thirty (30)                days                following such written notice; provided, however, that any failure                of a                non-breaching party to exercise this termination right with respect                to                certain breaches will not be deemed a waiver of the ability of such                non-breaching party to exercise this right upon any subsequent breach. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | To                the extent permitted by law, each party will have the right to terminate                this Agreement immediately upon notice to the other party, if such                other                party is declared bankrupt or insolvent, if there is an assignment                for the                benefit of creditors, or if a receiver is appointed or proceedings                commenced (and not dismissed within sixty (60) days), voluntarily                or                involuntarily, under any bankruptcy or similar                law. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Each                party will have the right to terminate this Agreement at any time,                at                will, upon one (1) year’s prior written notice to the other party. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.3** | **Automatic                Termination**.                This Agreement will automatically terminate upon the termination                or                expiration of the Collaboration Agreement. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.4** | *                *                * |
|--------|---------|-------------------------------------|

|   | **9.5** | **Failure                to Meet Detailed Requirements**. (a)                Notwithstanding any provision in this Agreement to the contrary,                in the                event that either party (the “**Nonperforming                Party**”)                fails to perform at least *** of the minimum number of Details such                party                is required to perform during any Calendar Year and the other party                (the                “**Performing                Party**”)                has performed at least *** of the minimum number of Details it is                required                to perform during such Calendar Year, such Performing Party will                have                sixty (60) days from its receipt of the Nonperforming Party’s final Detail                Report for such Calendar Year to notify the Nonperforming Party that                it is                in breach of such obligations, in which event the Nonperforming Party                will                have the opportunity to cure such default (in addition to any right                to                cure under Section 8.3 hereof) by providing a sufficient number of                extra                Details to make up for such short fall prior to the end of the first                full                Calendar Quarter following the Calendar Quarter in which the Performing                Party provides such breach notice to the Nonperforming Party. In                the event                the Nonperforming Party fails to so cure such default, the Performing                Party may, by providing written notice within thirty (30) days after                the                end of such Calendar Quarter, terminate this Agreement on sixty (60)                days’                prior notice to the Nonperforming Party. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | (b) | If                the Performing Party fails to give timely notice of the Nonperforming                Party’s breach or of termination due to the Nonperforming Party’s failure                to cure such breach in accordance with this Section 9.5, the Performing                Party will be deemed to have waived its rights under this Section                9.5 with                respect to such breach; provided, however, that any such waiver will                not                be construed as a waiver of such Performing Party’s rights under this                Section 9.5 as to any further breaches by the Nonperforming Party.                Notwithstanding the foregoing, the parties agree that the Nonperforming                Party will not be in breach of its Detailing obligations for any                Calendar                Year hereunder if the Nonperforming Party provides at least *** of                the                minimum number of Details it is required to perform during such Calendar                Year, and, for purposes of determining whether such *** has been                reached,                a Nonperforming Party may include any Excess Details (i) that were                performed by the Performing Party during such Calendar Year pursuant                to                Section 8.3 and (ii) for which the Nonperforming Party has paid the                Performing Party. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.6** | **Effects                of Termination**. (a)                Neither the termination nor expiration of this Agreement will release                or                operate to discharge either party from any liability or obligation                that                may have accrued prior to such termination or expiration. Any termination                of this Agreement as provided herein will not be an exclusive remedy                but                will be in addition to any remedies whatsoever that may be available                to                the terminating party. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Notwithstanding                the giving of any notice of termination pursuant to this Article                9, each                party will continue to fulfill its obligations under this Agreement                at all                times until the effective date of any such                termination. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.7** | **Actions                Upon Termination**.                Upon the termination or expiration of this Agreement for any reason,                Inyx                will immediately cease all of its promotional and Detailing activities                for                the Products, discontinue any use of the Trademarks, and return to                King or                destroy all sales training, Marketing Materials for the Products                containing Trademarks, and any remaining Products samples (not already                distributed or destroyed with destruction certified by Inyx). After                any                termination, King will retain the right to use any sales training                and                Marketing Materials developed under the auspices of the AMC during                the                term of this Agreement, provided, however, that King will have no                further                right to use Inyx’s name or logos in connection                therewith. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.8** | **Survival**.                The provisions of Articles 8 (to the extent applicable pursuant to                Section                9.9), 9, 10, and 11 and Sections 2.2(b) and 4.3(c) (with respect                to                furnishing a final report) will survive any expiration or termination                of                this Agreement. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **9.9** | **Payments                Upon Termination**. (a)                The expiration or termination of this Agreement pursuant to this                Article 9                will not release either party from any obligation to pay to the other                party any amounts accrued under Article 8 of this Agreement in connection                with activities completed, Marketing Costs accrued, and Net Sales                realized                with respect to the period prior to the effective date of such expiration                or termination. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Within                thirty (30) days after the expiration or termination of this Agreement,                Inyx will provide to the AMC and King (i) an Inyx Detail Report                for                the month during which such expiration or termination occurs (and                all Inyx                Detail Reports for prior months that were required to be submitted                to the                AMC and King pursuant to Section 3.4 but were not submitted); (ii) a                reasonably detailed statement of Marketing Costs incurred by Inyx                during                the period of January 1 of the Calendar Year in which such                expiration                or termination occurs through the effective date of such expiration                or                termination; and (iii) a reasonably detailed statement of                costs and                expenses incurred by Inyx in performing Excess Details, if any, during                such period. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Within                thirty (30) days after the expiration or termination of this Agreement,                King will provide to the AMC and Inyx (i) a King Detail Report                for                the month during which such expiration or termination occurs (and                all King                Detail Reports for prior months that were required to be submitted                to the                AMC and Inyx pursuant to Section 4.3 but were not submitted); (ii) a                reasonably detailed statement of Marketing Costs incurred by King                during                the period of January 1 of the Calendar Year in which such expiration                or                termination occurs through the effective date of such expiration                or                termination; (iii) a reasonably detailed statement of costs and expenses                incurred by King in performing Excess Details, if any, during such                period;                and (iv) a statement of Net Sales during such                period. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Within                thirty (30) days after receipt of such information from King and                Inyx, the                AMC will determine the net amounts due and or payable by Inyx and                King,                and such amounts will be paid by the parties within thirty (30) days                after                such AMC determination. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **10.** | **COLLABORATION                AGREEMENT** |
|---------|--------------------------------------------|

|   | **10.1** | **AMC                and Dispute Resolution**. (a)                The parties acknowledge and agree that the provisions with respect                to the                AMC in Article 2 of the Collaboration Agreement, including the dispute                resolution provisions in Section 2.7 of the Collaboration Agreement,                will                apply with respect to the parties activities under this                Agreement. |
|--------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | (b) | In                addition to the specific matters addressed in the Collaboration Agreement                and elsewhere in this Agreement, and subject to the other provisions                of                the Collaboration Documents, including King’s final decision-making                authority, as set forth in Section 2.7(c) of the Collaboration Agreement,                during the Term, the AMC will approve the                following: |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | marketing                and promotion activities for the                Products; |
|--------|-----|------------------------------------------------------------------------------------|

|   | (ii) | the                market definition against which the Products will be                measured; |
|--------|------|--------------------------------------------------------------------------------------------------|

|   | (iii) | Products                production forecasts; |
|--------|-------|-----------------------------------------------|

|   | (iv) | Marketing                Costs; |
|--------|------|---------------------------------|

|   | (v) | targets                for sales force staffing, number, and frequency of quarterly and                annual                Details; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------|

|   | (vi) | Products                positioning, strategy, and                objectives; |
|--------|------|-------------------------------------------------------------------------------|

|   | (vii) | determination                of the format and quantities of promotional sales, marketing, and                educational materials for the Products that will be provided to the                Physicians called upon in the Details by either party’s sales                representatives; and |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (viii) | quantities                and schedule of delivery of Products samples to be provided to each                party’s sales representatives and to the Physicians called upon in the                Details by each party’s sales                force. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **10.2** | **Recordkeeping                and Audits**.                The parties acknowledge and agree that the provisions governing                recordkeeping and audit rights contained in Article 10 of the                Collaboration Agreement will apply with respect to the parties activities                under this Agreement and are incorporated                herein. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **10.3** | **Confidentiality**.                The parties acknowledge and agree that the confidentiality obligations                set                forth in Section 12 of the Collaboration Agreement are incorporated                herein                in their entirety. |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **10.4** | **Indemnification                and Insurance**.                The parties acknowledge and agree that the provisions governing                indemnification and insurance contained in Article 13 of the Collaboration                Agreement will apply with respect to the parties activities under                this                Agreement and are incorporated                herein. |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **10.5** | **Competitor                Products**.                Inyx acknowledges and agrees that it is subject to the non-competition                provisions of Section 7.1 of the Collaboration Agreement, which provisions                will continue throughout the term of the Collaboration Agreement                notwithstanding the termination or expiration of this                Agreement. |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

| **11.** | **MISCELLANEOUS                PROVISIONS** |
|---------|---------------------------------------------|

|   | **11.1** | **Notices**.** **Except                as otherwise specifically provided herein, any notice or other documents                to be given under this Agreement will be in writing and will be deemed                to                have been duly given if sent by registered post, nationally recognized                overnight courier, or confirmed facsimile transmission to a party                (followed by hard copy by mail), or delivered in person to a party                at the                address or facsimile number set out below for such party or such                other                address as the party may from time to time designate by written notice                to                the other: |
|--------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **11.2** | **Assignment**.                Inyx may not assign or otherwise transfer this Agreement or any interest                herein or right hereunder without the prior written consent of King,                and                any such purported assignment, transfer, or attempt to assign or                transfer                any interest herein or right hereunder will be void and of no effect.                King                may freely assign and otherwise transfer this Agreement or any interest                herein or right hereunder without Inyx’s consent. Subject to the                foregoing, this Agreement will be binding upon and inure to the benefit                of                the parties hereto and their respective permitted successors and                assigns. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.3** | **Governing                Law**.                This Agreement will be construed under and in accordance with, and                governed in all respects by, the laws of the State of New York, without                regard to its conflicts of law                principles. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.4** | **Non-Waiver**.                The failure of either party to enforce or to exercise, at any time                or for                any period of time, any term of or any right arising pursuant to                this                Agreement does not constitute, and will not be construed as, a waiver                of                such term or right, and will in no way affect that party’s right later to                enforce or exercise such term or                right. |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.5** | **Entire                Agreement**.                This Agreement, together with the other Collaboration Documents,                contains                all of the terms agreed to by the parties regarding the subject matter                hereof and thereof and supersede any prior agreements, understandings,                or                arrangements between them, whether oral or in writing. This Agreement                may                not be amended, modified, altered, or supplemented except by means                of a                written agreement or other instrument executed by both of the parties                hereto. No course of conduct or dealing between the parties will                act as a                modification or waiver of any provisions of this                Agreement. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.6** | **Consent                to Jurisdiction**.                Each of the parties hereby submits to the exclusive general jurisdiction                of the courts of the State of New York and the courts of the United                States                of America for the Eastern District of New York in any action or                proceeding arising out of or relating to this Agreement and to the                jurisdiction of the appellate courts to which appeals are required                to be                taken from any of the foregoing. Each of the parties waives any defense                of                inconvenient forum to the maintenance of any such action or proceeding.                Any party may make service on any other party by sending or delivering                a                copy of the process to the party to be served at the address and                in the                manner provided for the giving of notices in Section 11.1 above.                Nothing                in this Section 11.6, however, will affect the right of any party                to serve                legal process in any other manner permitted by law or                equity. |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **11.7** | **Equitable                Relief**.                Each party acknowledges that a breach by it of the provisions of                this                Agreement cannot reasonably or adequately be compensated in damages                in an                action at law and that such a breach may cause the other party irreparable                injury and damage. By reason thereof, each party agrees that the                other                party is entitled to seek, in addition to any other remedies it may                have                under this Agreement or otherwise, preliminary and permanent injunctive                and other equitable relief to prevent or curtail any breach of this                Agreement by the other party; provided, however, that no specification                in                this Agreement of a specific legal or equitable remedy will be construed                as a waiver or prohibition against the pursuing of other legal or                equitable remedies in the event of such a breach. Each party agrees                that                the existence of any claim, demand, or cause of action of it against                the                other party, whether predicated upon this Agreement, or otherwise,                will                not constitute a defense to the enforcement by the other party, or                its                successors or assigns, of the covenants contained in this                Agreement. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.8** | **Severability**.                In the event that any of the provisions or a portion of any provision                of                this Agreement is held to be invalid, illegal, or unenforceable by                a court                of competent jurisdiction or a governmental authority, such provision                or                portion of provision will be construed and enforced as if it had                been                narrowly drawn so as not to be invalid, illegal, or unenforceable,                and the                validity, legality, and enforceability of the enforceable portion                of any                such provision and the remaining provisions will not be adversely                affected                thereby. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.9** | **Relationship                of the Parties**.                The parties hereto are acting and performing as independent contractors,                and nothing in this Agreement creates the relationship of partnership,                joint venture, sales agency, or principal and agent. Neither party                is the                agent of the other, and neither party may hold itself out as such                to any                other party. All financial obligations associated with each party’s                business will be the sole responsibility of such                party. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.10** | **Counterparts**.                This Agreement will become binding when any one or more counterparts                hereof, individually or taken together, will bear the signatures                of each                of the parties hereto. This Agreement may be executed in any number                of                counterparts, each of which will be deemed an original as against                the                party whose signature appears thereon, but all of which taken together                will constitute but one and the same                instrument. |
|--------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL          TREATMENT**

----

|   | **11.11** | **Force                Majeure**.                Neither party will be liable to the other party for any failure to                perform                as required by this Agreement if the failure to perform is due to                circumstances reasonably beyond such party’s control including acts of                God, civil disorders or commotions, acts of aggression, fire, explosions,                floods, drought, war, sabotage, embargo, utility failures, material                shortages, a national health emergency, or appropriations of property.                A                party whose performance is affected by a *force                majeure*                event will take prompt action using its reasonable best efforts to                remedy                the effects of the *force                majeure*                event. If, as a result of a *force                majeure*                event, a party is unable to fully perform its obligations hereunder                for                any consecutive period of one hundred eighty (180) days, the other                party                will have the right to terminate this Agreement, upon providing written                notice to the nonperforming party, such termination to be effective                thirty                (30) days from the date of such notice. |
|--------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.12** | **Interpretation**.                The parties hereto acknowledge and agree that: (a) each party and                its                representatives have reviewed and negotiated the terms and provisions                of                this Agreement and have contributed to its revision; and (b) the                terms and                provisions of this Agreement will be construed fairly as to each                party                hereto and not in favor of or against either party regardless of                which                party was generally responsible for the preparation or drafting of                this                Agreement. |
|--------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.13** | **Third                Party Beneficiaries**.                This Agreement is not intended to confer upon any non-party rights                or                remedies hereunder, except as may be received or created as part                of a                valid assignment. |
|--------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.14** | **Use                of Party’s Name**.                Except as expressly provided or contemplated hereunder and except                as                otherwise required by applicable law, no right is granted pursuant                to this                Agreement to either party to use in any manner the trademarks or                name of                the other party, or any other trade name, service mark, or trademark                owned                by or licensed to the other party in connection with the performance                of                the Agreement. Notwithstanding the above, either party will be permitted                to use the other party’s name and marks, as may be required under                applicable law, in connection with securities or other public                filings. |
|--------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

***[Signatures      on following page]***

**CONFIDENTIAL          TREATMENT**

----

|         |                                    |                                 |
|--------------|-----------------------------------------|--------------------------------------|
|         | KING              PHARMACEUTICALS, INC. |
|    |                               |                            |
|         | By:                           | /s/ Brian              Markison |
|         | Brian              Markison             |
|         | President              and CEO          |

|         |                          |                               |
|--------------|-------------------------------|------------------------------------|
|         | INYX,              INC.       |
|    |                     |                          |
|         | By:                 | /s/ Jack              Kachkar |
|         | Jack              Kachkar     |
|         | Chairman              and CEO |

**CONFIDENTIAL          TREATMENT**

----

**SCHEDULE      2.2**

**TRADEMARKS**

| **Country**  | **Mark**  | **Registration                Number**  |
|-------------------|----------------|----------------------------------------------|
| U.S.         | INTAL     | 876359                                  |
| U.S.         | TILADE    | 1259079                                 |
| Canada       | INTAL     | 164043                                  |
| Canada       | TILADE    | 394582                                  |

**CONFIDENTIAL          TREATMENT**

----

**SCHEDULE      8.1**

**BASELINE      AMOUNTS**

| *Calendar                Year*  | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  |
|--------------------------------------|------------|------------|------------|------------|------------|------------|------------|------------|
| *Net                Sales*      | ***   | ***   | ***   | ***   | ***   | ***   | ***   | ***   |

**CONFIDENTIAL          TREATMENT**

----